The TIDE database showed that the patients with high-expressed RAB42 had a better prognosis treated with PD1 or CTLA4 inhibitors in melanoma (dbGaP Study Accession: phs000452.v3.p1) (Figure 7C). Here, CTLA4 is linked to melanoma.